The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX
Abstract
Objective: The aim of this study was to determine (1) whether preoperative factors can predict resectability of borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant FOLFIRINOX, (2) which patients might benefit from adjuvant therapy, and (3) survival differences between resected BR/LA patients who received neoadjuvant FOLFIRINOX and upfront resected patients. Background: Patients with BR/LA PDAC are often treated with FOLFIRINOX to obtain a margin-negative resection, yet selection of patients for resection remains challenging. Methods: Clinicopathologic data of PDAC patients surgically explored between 04/2011-11/2016 in a single institution were retrospectively collected. Results: Following neoadjuvant FOLFIRINOX, 141 patients were surgically explored (BR: 49%, LA: 51%) and 110 (78%) were resected. Resected patients had lower preoperative CA 19-9 levels (21 vs 40 U/mL, P = 0.03) and smaller tumors on preoperative computed tomography (CT) scan (2.3 vs 3.0 cm, P = 0.03), but no predictors of resectability were identified. Median overall survival (OS) was 34.2 months from diagnosis for all FOLFIRINOX patients and 37.7 months for resected patients. Among resected patients, preoperative CA 19-9 >100 U/mL and >8 months between diagnosis and surgery predicted a shorter postoperative disease-free survival (DFS); Charlson comorbidity index >1, preoperative CA 19-9 >100 U/mL and tumor size (>3.0 cm on CT or >2.5 cm on pathology) predicted decreased OS. DFS and OS were significantly better for BR/LA PDAC patients treated with neoadjuvant FOLFIRINOX compared with upfront resected patients (DFS: 29.1 vs 13.7, P < 0.001; OS: 37.7 vs 25.1 months from diagnosis, P = 0.01). Conclusion: BR/LA PDAC patients with no progression on neoadjuvant FOLFIRINOX should be offered surgical exploration. Except size, traditional pathological parameters fail to predict survival among resected FOLFIRINOX patients. Resected FOLFIRINOX patients have survival that appears to be superior than that of resectable patients who go directly to surgery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Gillen, S., Schuster, T., Meyer zum Büschenfelde, C., Friess, H., & Kleeff, J. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000267 · Cited by 1,552
Suker, M., Beumer, B. R., Sadot, E., Marthey, L., Faris, J. E., Mellon, E. A., El-Rayes, B. F., Wang-Gillam, A., Lacy, J., Hosein, P. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00172-8 · Cited by 939
Self-citationCallery, M. P., Chang, K. J., Fishman, E. K., Talamonti, M. S., William Traverso, L., & Linehan, D. C. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0408-6 · Cited by 902
Ferrone, C. R., Marchegiani, G., Hong, T. S., Ryan, D. P., Deshpande, V., McDonnell, E. I., Sabbatino, F., Santos, D. D., Allen, J. N., Blaszkowsky, L. S., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000867 · Cited by 842
Self-citationKatz, M. H. G., Fleming, J. B., Bhosale, P., Varadhachary, G., Lee, J. E., Wolff, R., Wang, H., Abbruzzese, J., Pisters, P. W. T., Vauthey, J., et al. (2012) · Cancer · doi:10.1002/cncr.27636 · Cited by 536
Konstantinidis, I. T., Warshaw, A. L., Allen, J. N., Blaszkowsky, L. S., Castillo, C. F.-D., Deshpande, V., Hong, T. S., Kwak, E. L., Lauwers, G. Y., Ryan, D. P., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318263da2f · Cited by 424
Self-citationMokdad, A. A., Minter, R. M., Zhu, H., Augustine, M. M., Porembka, M. R., Wang, S. C., Yopp, A. C., Mansour, J. C., Choti, M. A., & Polanco, P. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.5081 · Cited by 400
Faris, J. E., Blaszkowsky, L. S., McDermott, S., Guimaraes, A. R., Szymonifka, J., Huynh, M. A., Ferrone, C. R., Wargo, J. A., Allen, J. N., Dias, L. E., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0435 · Cited by 278
Self-citation
Cited by
Optimizing the outcomes of pancreatic cancer surgery
Strobel, O., Neoptolemos, J., Jäger, D., & Büchler, M. W. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0112-1 · Cited by 943
Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection
Gemenetzis, G., Groot, V. P., Blair, A. B., Laheru, D. A., Zheng, L., Narang, A. K., Fishman, E. K., Hruban, R. H., Yu, J., Burkhart, R. A., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000002753 · Cited by 401
Janssen, Q. P., Buettner, S., Suker, M., Beumer, B. R., Addeo, P., Bachellier, P., Bahary, N., Bekaii-Saab, T., Bali, M. A., Besselink, M. G., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz073 · Cited by 297
Metadata
- Authors
- Michelakos, T., Pergolini, I., Castillo, C. F.-D., Honselmann, K. C., Cai, L., Deshpande, V., Wo, J. Y., Ryan, D. P., Allen, J. N., Blaszkowsky, L. S., Clark, J. W., Murphy, J. E., Nipp, R. D., Parikh, A., Qadan, M., Warshaw, A. L., Hong, T. S., Lillemoe, K. D., & Ferrone, C. R.
- Venue
- Annals of Surgery
- Published
- 2019-04
- Volume
- 269
- Issue
- 4
- Pages
- 733-740
- ISSN
- 0003-4932 (ISSN-L)
- 1528-1140
- OpenAlex
- W2772770935
- Cited by
- 324
- References
- 18
- FWCI
- 10.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. https://app.cochat.ai/papers/10.1097/sla.0000000000002600
- The paper
- Michelakos, T., Pergolini, I., Castillo, C. F.-D., Honselmann, K. C., Cai, L., Deshpande, V., Wo, J. Y., Ryan, D. P., Allen, J. N., Blaszkowsky, L. S., Clark, J. W., Murphy, J. E., Nipp, R. D., Parikh, A., Qadan, M., Warshaw, A. L., Hong, T. S., Lillemoe, K. D., & Ferrone, C. R. (2019). Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Annals of Surgery. https://doi.org/10.1097/sla.0000000000002600
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.